Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives

J Cell Physiol. 2019 Feb;234(2):1237-1247. doi: 10.1002/jcp.27137. Epub 2018 Sep 7.

Abstract

Prostate cancer is a major cause of cancer-related death in males. Wnt/β-catenin signaling plays a critical role in the pathogenesis of this disease by regulating angiogenesis, drug resistance, cell proliferation, and apoptosis. Suppression of Wnt canonical or noncanonical signaling pathways via Wnt biological or pharmacological antagonists is a potentially novel therapeutic approach for patients with prostate cancer. This review summarizes the role of Wnt signaling inhibitors in the pathogenesis of prostate cancer for a better understanding and hence a better management of this disease.

Keywords: Wnt antagonists; Wnt signaling; prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Male
  • Molecular Targeted Therapy
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • Wnt Proteins / antagonists & inhibitors*
  • Wnt Proteins / metabolism
  • Wnt Signaling Pathway / drug effects*

Substances

  • Antineoplastic Agents
  • Wnt Proteins